Previous 10 | Next 10 |
2023-10-03 10:07:00 ET Wall Street analysts are quite bullish right now on gene-editing specialist Intellia Therapeutics (NASDAQ: NTLA) -- expecting, on average, the stock to soar 167% in the coming 12 months. Yet, Intellia has a very long way to go before it has a chance to commerc...
2023-10-03 07:40:17 ET More on Intellia, Regeneron, etc. Intellia Therapeutics: Massive OpEx Begin To Weigh On HAE Prospects Regeneron Pharmaceuticals: Game-Changing Discoveries In Healthcare Regeneron Pharmaceuticals, Inc. (REGN) Morgan Stanley 21st Annual Global He...
Collaboration combines Intellia’s leading genome editing platform, including its proprietary Nme2Cas9 technology, with Regeneron’s proprietary antibody-targeted viral vector delivery technologies to jointly advance in vivo programs outside of the liver for neurological and muscu...
2023-10-02 12:39:24 ET Summary Intellia Therapeutics' high R&D expenses drive $132.3M operating loss but robust liquidity and 27-month cash runway offer financial cushion. NTLA-2002 for HAE shows transformative Phase 1 results, becoming a key asset despite mixed market sentime...
2023-09-23 09:45:00 ET Intellia Therapeutics (NASDAQ: NTLA) and Rocket Pharmaceuticals (NASDAQ: RCKT) are gene-editing biotechs that want to offer what few others can: cures for hereditary afflictions that have so far proved beyond the reach of medical science. But for the m...
2023-09-19 07:35:00 ET Other than running out of money, what economic risk do Intellia Therapeutics , (NASDAQ: NTLA) CRISPR Therapeutics , (NASDAQ: CRSP) Bluebird Bio , (NASDAQ: BLUE) and a bunch of other cutting-edge gene-editing biotechs have in common? There are a...
2023-09-10 08:15:00 ET Cathie Wood is known for her propensity to buy growth stocks that have the chance to disrupt their industries while also making early investors rich. And that means she's a big buyer of biotech stocks via her ARK Innovation ETF (NYSEMKT: ARKK) . She's been par...
2023-09-06 14:00:00 ET Superstar investor Cathie Wood is increasing her bet on a cutting-edge technology that could transform the treatment of many diseases. I'm talking about gene editing. Wood has been progressively increasing her stake in specialist Intellia Therapeutics (NASDA...
2023-08-23 08:25:00 ET Unprofitable clinical-stage biotechs have lost their appeal in the past year, given the challenging economic and market conditions we still haven't entirely left behind. That's why companies such as Editas Medicine (NASDAQ: EDIT) and Intellia Therapeutics ...
2023-08-14 08:15:00 ET Summary This article provides a dashboard with industry metrics in healthcare, then focus on the Global X Genomics & Biotechnology ETF. Pharmaceuticals/biotechnology and healthcare providers have fair value and quality scores. Healthcare equipment is...
News, Short Squeeze, Breakout and More Instantly...
Intellia Therapeutics Inc. Company Name:
NTLA Stock Symbol:
NASDAQ Market:
Intellia Therapeutics Inc. Website:
CAMBRIDGE, Mass., July 24, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that it awarded inducement grants on July 22, 2024 to its Executive Vice Pr...
2024-07-23 12:52:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...